Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 6
1993 7
1994 3
1995 4
1996 6
1997 6
1998 3
1999 5
2000 15
2001 17
2002 24
2003 18
2004 27
2005 35
2006 29
2007 41
2008 53
2009 64
2010 64
2011 62
2012 63
2013 61
2014 84
2015 104
2016 85
2017 98
2018 118
2019 147
2020 144
2021 179
2022 203
2023 185
2024 81

Text availability

Article attribute

Article type

Publication date

Search Results

1,856 results

Results by year

Filters applied: . Clear all
Page 1
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy.
Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, Xiang B, Xiong W, Dai P, Mao Q, Xing X, Yao Y, Yu H, Xu G, Li S, Ren Y, Chen B, Jiang C, Meng G, Lee YR, Wei W, Freeman GJ, Xie C, Zhang J. Xiao X, et al. Among authors: bu x. Nat Commun. 2023 May 19;14(1):2859. doi: 10.1038/s41467-023-38605-3. Nat Commun. 2023. PMID: 37208329 Free PMC article.
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. van der Heijde D, et al. Among authors: bu x. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788492 Free PMC article. Clinical Trial.
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.
Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J, Zhang T, Song W, Xiao X, Sun Y, Xiong W, Shi J, Dai P, Xiang B, Duan H, Yan X, Wu F, Zhang WC, Lin D, Hu H, Zhang H, Slack FJ, He HH, Freeman GJ, Wei W, Zhang J. Yu H, et al. Among authors: bu x. Cell Chem Biol. 2024 Apr 18;31(4):776-791.e7. doi: 10.1016/j.chembiol.2023.09.001. Epub 2023 Sep 25. Cell Chem Biol. 2024. PMID: 37751743
1,856 results